Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Federal grantsHow to Find Grants for Nonprofits
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to apply for a grantGrant Applications vs. RFPs: Writing Differences Explained
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Closed bids
  3. ›Federal
  4. ›Revision Applications for Incorporation of Novel NCI…

U.S. National Institutes of Health·United States of America

Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)

Closes 12/9/2025$150kGrants Notice
Bid source

This opportunity has closed.

Bid Banana tracks 1.6M+ bids and awards across all 50 states. Save a search and we'll email your new matches, daily or weekly — so the next one reaches you with time to bid.

Get alerted next time

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or device developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. * The NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery. * The program supports research in the area of cancer detection and diagnosis. * Eligible applicants include various organizations such as independent school districts, for-profit organizations, non-profits, city or township governments, and public housing authorities. * The estimated funding for this opportunity is $150,000, and the award ceiling is also $150,000.

Attached files

Contact

[email protected]

301-402-2541

Key dates

Opened
12/31/2024
Closes
12/9/2025

Last updated

Details

Type
Grants Notice
Industry
Healthcare and Medical Services
NAICS
541710
Solicitation №
RFA-CA-25-006

Budget estimate

$150,000

The Award Ceiling is explicitly stated on the source site.

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one too late. Don't find the next one too late.

Bid Banana searches open government bids across all 50 states, updated daily. Save a search once and we email you your new matches, daily or weekly, while there is still time to win them.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 83%

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

83% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

83% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

83% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

81% match

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Closes 1/7/2027Opened 12/15/2023

U.S. National Institutes of Health·United States of America

81% match

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)

Closes 1/7/2028Opened 3/25/2021

U.S. National Institutes of Health·United States of America

80% match

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Closes 1/7/2028Opened 11/6/2024

U.S. National Institutes of Health·United States of America

80% match

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Closes 1/7/2027Opened 12/15/2023

U.S. National Institutes of Health·United States of America

80% match

Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Closes 6/10/2027Opened 7/28/2026

U.S. National Institutes of Health·United States of America

80% match

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Closes 10/19/2027Opened 7/2/2025

U.S. National Institutes of Health·United States of America

80% match

Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

Closes 11/15/2027Opened 12/16/2024

U.S. National Institutes of Health·United States of America

80% match

Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)

Closes 7/5/2029Opened 6/16/2025

U.S. National Institutes of Health·United States of America

79% match

Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

Closes 1/7/2027Opened 8/8/2023

U.S. National Institutes of Health·United States of America

79% match

National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)

Closes 1/24/2027Opened 6/9/2026

U.S. National Institutes of Health·United States of America

79% match

Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Closes 9/25/2028Opened 11/26/2025

U.S. National Institutes of Health·United States of America

78% match

Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)

Closes 2/9/2027Opened 11/21/2025

U.S. National Institutes of Health·United States of America

78% match

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

Closes 1/7/2028Opened 1/11/2022

U.S. National Institutes of Health·United States of America

78% match

Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Closes 1/24/2027Opened 3/10/2026

U.S. National Institutes of Health·United States of America

78% match

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)

Closes 9/25/2029Opened 9/9/2025

U.S. National Institutes of Health·United States of America

78% match

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

Closes 11/17/2026Opened 8/1/2023

U.S. National Institutes of Health·United States of America

78% match

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

Closes 11/17/2026Opened 12/20/2023

U.S. National Institutes of Health·United States of America

78% match

Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)

Closes 1/25/2027Opened 8/28/2025

U.S. National Institutes of Health·United States of America

77% match

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

Closes 10/8/2027Opened 12/18/2024

U.S. National Institutes of Health·United States of America

77% match

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Closes 2/11/2028Opened 11/7/2024

U.S. National Institutes of Health·United States of America

77% match

Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)

Closes 10/11/2029Opened 3/10/2026